Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, 041b47)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal encapsulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio. It is designed to optimize the synergistic delivery of these two chemotherapy agents to leukemia cells while reducing systemic toxicity. Cytarabine is a pyrimidine nucleoside analog that inhibits DNA polymerase and DNA synthesis, while daunorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II. This formulation allows for prolonged exposure and preferential uptake by bone marrow cells. Originally developed by Celator Pharmaceuticals (later acquired by Jazz Pharmaceuticals), CPX-351 is primarily indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It is also being investigated for use in pediatric populations with secondary myeloid neoplasms.
- Brand names
- Vyxeos
- Other names
- Liposomal daunorubicin-cytarabineDaunorubicin-cytarabine liposomeLiposomal cytarabine and daunorubicin
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, 041b47).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, 041b47).